Peripheral Arterial Disease
Nine cases spanning claudication management, carotid and aortic disease, and acute vascular emergencies — choose a case below to open its full multi-voice debate.
Cilostazol is a Class I recommendation for her claudication, and she doesn't have diagnosed heart failure. An incidental echo finding sits close enough to the drug's real contraindication that the guideline's confidence stops feeling sufficient on its own.
A single patient for whom both guideline-endorsed first-line treatments for claudication are correct in principle, and only one of them is realistically reachable this month.
CREST-2 has now reported, and it compared revascularization against intensive medical therapy — but he has never actually received the intensive regimen that formed the trial's comparison arm.
His leg is salvageable but the clock matters — and the choice between dissolving the clot over hours or removing it surgically within the hour turns on how much time his own collateral circulation actually provides.
He hasn't crossed the standard size threshold for repair, but his active smoking and currently favorable anatomy for a less invasive procedure both push against simply waiting.
His acute presentation meets every criterion for uncomplicated disease, where medical management is the clear standard — the real debate is whether specific anatomic features on his imaging justify preemptive repair anyway.
The major trials found no benefit to stenting over medical therapy for most patients with this finding — but her flash pulmonary edema and still-refractory blood pressure fall outside the population those trials specifically isolated.
A single patient, ninety minutes into a bowel that is ischemic but not yet dead. The disagreement isn't about which drug to start — heparin starts regardless — it's about which team reaches him first, and how long that window stays open.
A single patient whose disease is severe enough that intervention looks inevitable to one specialist and premature to another. The disagreement isn't about which drugs start today — all of them do — it's about how much runway a trial of them deserves before the vessel itself gets fixed surgically.